Abstract
Sepsis is one of the most common causes of death in ICU and especially is a harmful and a life-threatened disease to pediatrics in the world. It has been demonstrated that IL-3 plays an essential role in the processing of sepsis and the inhibition of IL-3 may alleviate sepsis progress. In our previous study, we selected a novel CD123 aptamer successfully which could inhibit the interaction of CD123 and IL-3. The aim of this study is to explore the protection ability of the first thioaptamer SS30 against sepsis in a cecal ligation and puncture (CLP) rat model. Serum IL-3 level of sepsis patients was assessed by ELISA. CLP rat model was applied in all experimental groups. CD123 thioaptamer SS30 and CD123 antibody were used to block the recognition between IL-3 and CD123. Body weight, temperature, blood gas, MAP, and serum cytokines of four grouped rats were assessed. Flow cytometry was utilized to evaluate JAK2 and STAT5 proteins. After the administration of SS30 or CD123 antibody, the rats in SS30 and CD123 antibody group had lower cytokines values(lactate, TNF-α, IL-1β, and IL-6), whereas exhibited higher value of core temperature, MAP, PO2/FiO2, and ETCO2 than those in the CLP group. The expression level of phosphorylated JAK2 and STAT5 was declined and the survival rate of rats was increased. In addition, the protection ability of SS30 was better than CD123 antibody. Therefore, CD123 thioaptamer SS30 could reduce mortality by down-regulating the phosphorylated JAK2/STAT5 signaling pathway, and reduce serum cytokines which involving in sepsis development in CLP rat model.
Keywords:
Acknowledgments
We would like to thank everyone who generously agreed to be interviewed for this research.
Declarations
Consent for publication
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
Availability of data and materials
All data concerning the case are presented in the manuscript.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
This is a research article and all authors have read and approved the manuscript. Authors’ contribution: conceived and designed the experiments: L.Z. and J.Z.; Performed the experiments: J.Z., M.W., Y.Y., G.W., F.C., and Q.L.; Analyzed the data: L.Z.; Contributed reagents/materials/analysis tools: Y.Y., G.W., F.C., and Q.L.; Wrote the paper: L.Z.
Compliance with ethical standards
Disclosure statement
The authors declare that they have no conflict of interest.
Ethical approval
The protocol of the study using patient samples and the animal study in this paper was reviewed and approved by the Ethics Committee of Xi’an Jiaotong University Affiliated Children’s Hospital (Xi’an Children’s Hospital, Xi’an, China), No. C2018004.
Informed consent
Informed consent was obtained from all individual participants included in the study.